Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.60 |
| ▸ | DNMT3A | Q9Y6K1 | 3/20 | 0.60 |
| ▸ | NSD2 | O96028 | 7/20 | 0.57 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.55 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.55 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15280249 | 0.92 | EHMT2 (0.69) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL16521334 | 0.88 | EHMT2 (0.63) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL15280265 | 0.87 | EHMT2 (0.77) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL20109379 | 0.87 | DNMT3A (0.79) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL15280229 | 0.83 | NSD2 (0.80) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL15280230 | 0.81 | LMNA (0.74) | EHMT2DNMT3ANSD2KDM1A | |
| SCHEMBL15280240 | 0.79 | MCHR1 (0.58) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL15280257 | 0.79 | EHMT2 (0.83) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL25363177 | 0.78 | NSD2 (0.69) | EHMT2DNMT3ANSD2EZH2KDM1A | |
| SCHEMBL15280258 | 0.78 | DNMT3A (0.79) | EHMT2DNMT3ANSD2EZH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | DNMT1, DNMT3A, DNMT3B | EHMT2 34/4885DNMT3A 2/4885NSD2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.